Abstract
As a first attempt at exploring an association between histaminergic and serotoninergic neuronal phenotypes in glucose regulation, the influence of the histamine H3 receptor antagonist thioperamide on glucose uptake by brain was determined in rats in which the serotoninergic innervations of brain was largely destroyed perinatally. Male Wistar rats were initially treated on the 3rd day after birth with the serotoninergic neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) (75 μg icv) or saline vehicle (10 μl icv). At 8 weeks lesioned and control rats were terminated in order to validate the effectiveness of 5,7-DHT: reduction in 5-HT and 5-HIAA by 83–91% and 69–83% in striatum, frontal cortex, and hippocampus (HPLC/ED method). Other groups of rats were pretreated with thioperamide (5.0 mg/kg ip) or saline vehicle 60 min prior to 6-[3H]-D-glucose (500 μCi/kg ip). Fifteen-min later rats were decapitated and brains were excised and dissected to remove frontal cortex, striatum, hippocampus, thalamus/hypothalamus, pons, and cerebellum. Liquid scintillation spectroscopy was used to determine that [3H]glucose uptake, which was enhanced in 5,7-DHT lesioned rats in cortex (by 88%), hippocampus, thalamus/hypothalamus, pons and cerebellum (each by 47–56%), and in striatum (by 35%). In contrast, thioperamide prevented the enhancement in [3H]glucose uptake in all brain regions of 5,7-DHT neonatally lesioned rats; and [3H]glucose levels were significantly different in all brain regions (except thalamus/hypothalamus) in thioperamide-versus saline-treated rats. These findings indicate a functional association between histaminergic and serotoninergic systems in brain in relation to glucose regulation.
References
Arrang JM, Goway M, Schwartz JC (1983) Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 302:812–817
Arrang JM, Gorbag M, Lancelot JC, Lacomite JM, Pollard H, Robba M, Schunack W, Schwartz JC (1987) Highly potent and selective ligands for histamine H3-receptors. Nature 327:117–123
Baumgarten HG, Lachenmayer L (1972) 5,7-Dihydroxytryptamine: improvement in chemical lesioning of indoleamine neurons in the mammalian brain. Z Zellforsch Mikrosk Anat 135(3):399–414
Brown RE, Stevans DR, Haas HL (2001) The physiology of brain histamine. Prog Neurobiol 63:637–672
Brus R, Kostrzewa RM, Perry KW, Fuller RW (1994) Supersensitization of the oral response to SKF 38393 in neonatal 6-hydroxydopamine-lesioned rats is eliminated by neonatal 5, 7-dihydroxytryptamine treatment. J Pharmacol Exp Ther 260:231–237
Brus R, Plech A, Kostrzewa RM (1995a) Enhanced quinpirole response in rats lesioned neonatally with 5, 7-dihydroxytryptamine. Pharmacol Biochem Behav 50:649–653
Brus R, Szkilnik R, Kostrzewa RM, Jędrusiak I, Konecki J, Głowacka M, Shani J (1995b) Modulation of glucose uptake in rat brain after administration of quinpirole and SKF-38393, two central dopamine receptor agonists. Pharmacol Comm 7:87–91
Darves AS, Gudelski GA (2003) Injection of 5-HT2 receptors induces glycogenolysis in the rat brain. Eur J Pharmacol 464:135–140
Freo U, Riechieri GL, Holloway H, Soncrant TT (1992) Time- and dose-dependent effects of the serotoninergic agent quipazine on regional cerebral metabolism in rats. Brain Res 600:249–256
Goodchild RE, Curt JA, Hobson I, Piggot MA, Perry RH, Ince P, Jaros E, Perry EK (1999) Distribution of histamine H3-receptor binding in the normal human basal ganglia: comparison with Huntington’s and Parkinson’s disease cases. Eur J Neurosci 11:449–456
Hommer D, Andreason P, Rio D, Williams W, Ruttimann U, Momenan R, Zametkin A, Rawlings R, Linnoila M (1997) Effect of m-chlorphenyepiperazine on regional brain glucose utilization: a positron emission subjects. J Neurosci 17:2796–2806
Hough LB (2001) Genomics meets histamine receptors: new subtypes, new receptors. Mol Pharmacol 59:415–419
Kostrzewa RM (2001) Mechanism of action of 6-hydroxydopamine, a dopaminergic neurotoxin. In: Segura-Aguilar J (ed) Mechanisms of degeneration and protection of the dopaminergic system. FP Graham Publishing Co, Johnson City, pp 89–104
Kostrzewa RM, Gong L, Brus R (1992) Serotonin (5-HT) system mediate dopamine (DA) receptor supersensitivity. Acta Neurobiol Exp 53:31–41
Kwieciński A, Nowak P (2009) Effect of prenatal manganese intoxication on (3H)glucose uptake in the brain of rats lesioned as neonates with 6-hydroxydopamine. Pharmacol Rep 61:558–563
Leckin A, Jarvikyla M, Tuomisto L (1994) The effect of metoprine on glicoprivic feeding induced by 2-deoxy-D-glucose. Pharmacol Biochem Behav 49:853–857
Magnusson O, Nilsson LB, Westerland D (1980) Simultaneous determination of dopamine, DOPAC, and homovanillic acid. Direct injection of supernatants from brain tissue homogenates in a liquid chromatography—electrochemical detection system. J Chromatogr 221:237–247
Molina PE, Williams P, Abumrad RN (1997) Histaminergic contribution to the metabolic agent of neuroglucopenia. Amer J Physiol 272:R1918–R1924
Molina-Hernández A, Nuñez A, Arias-Montaño JA (2000) Histamine H3 receptor activation inhibits dopamine synthesis in rat striatum. Neuroreport 11:163–166
Nishibori M, Itoh Y, Seaki K (1990) Effect of microinjection of histamine into the brain on plasma levels of epinephrine and glucose in freely moving rats. Jpn J Pharmacol 54:257–263
Nonagaki K, Igucki A, Li X, Tamagawa T, Watanabe G, Hiyoski Y, Sakamoto N (1972) Role of brain - histamine H1 and H2 receptors in neostignine-induced hyperglycemia in rats. Life Sci 51:PL131–PL134
Nowak P, Dąbrowska J, Bortel A, Biedka I, Szczerbak G, Kostrzewa RM, Brus R (2006) Histamine H3 receptor agonist- and antagonist evoked vacous chewing movements in 6-OHDA-lesioned rats occurs in absence of change in microdialysate dopamine level. Eur J Pharmacol 552:46–54
Nowak P, Szkilnik R, Korossy E, Noras Ł, Kostrzewa RM, Brus R (2008) Effect of histamine receptor antagonists on oral activity and stereotyped behaviors in neonatally 6-OHDA-lesioned rats (rodent model of Parkinson’s disease). Pharmacol Rep 60:288–289 abstract
Nowak P, Jochem J, Szkilnik R, Korossy E, Drab J, Bojanek K, Kostrzewa RM, Brus R (2009a) Histaminergic activity in adult rats neonatally lesioned with neurotoxins: DSP-4, 5, 7-DHT and 6-OHDA (rodent model of Parkinson’s disease). Pharmacol Rep 61:376 abstract
Nowak P, Noras Ł, Jochem J, Szkilnik R, Brus H, Kőrössy E, Drab J, Kostrzewa RM, Brus R (2009b) Histaminergic activity in a rodent model of Parkinson’s disease. Neurotox Res 15:246–251
Panula P, Arratosinen MS, Pilvoca U, Kostiloinen E (1990) A histamine-containing neuronal system in human brain. Neuroscience 29:127–182
Ryn JH, Yanai R, Sakurai E, Kim CY, Watanabe T (1995) Ontogenic development of histamine receptor subtype demonstrated by quantitative autoradiography. Develop Brain Res 87:101–110
Schwartz JC, Arrang JM, Garbarg M, Pollard H, Raut M (1991) Histaminergic transmission in the mammalian brain. Physiol Rev 71:1–51
Tabatabie T, Dryhurst G (2001) Molecular mechanisms of action of 5, 6- and 5, 7-dihydroxytryptamine. In: Kostrzewa RM (ed) Highly selective neurotoxins. Basic and clinical application. Humana Press, Tatowa, pp 269–291
Thurmond RL, Deais PJ, Durnford PF (2004) A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. J Pharmacol Exp Ther 309:404–413
Acknowledgments
Supported by Medical University of Silesia: KNW-1-001/08. The authors express their thanks to Mrs. U. Mikołajun and B. Mędrek for their excellent technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jośko, J., Drab, J., Nowak, P. et al. Thioperamide, an H3 Receptor Antagonist Prevents [3H]Glucose Uptake in Brain of Adult Rats Lesioned as Neonates with 5,7-Dihydroxytryptamine. Neurotox Res 20, 93–96 (2011). https://doi.org/10.1007/s12640-010-9216-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12640-010-9216-9